Skip to content

Efficacy and Safety of NP-2007 on Skin Health

A 12-week, Randomized, Double-Blind, Placebo-Controlled Human Clinical Study to Evaluate the Efficacy and Safety of Small-Molecular-Weight Deer Antler Collagen (NP-2007) for Improving Skin Health

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07486414
Enrollment
84
Registered
2026-03-20
Start date
2022-04-04
Completion date
2022-09-30
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Aging, Dry Skin

Brief summary

The objective of this study is to evaluate the efficacy and safety of Small-molecular-weight deer antler collagen (NP-2007) on skin health, including skin hydration, transepidermal water loss (TEWL), elasticity, and eye wrinkles.

Interventions

DIETARY_SUPPLEMENTNP-2007

500mg/day, once a day, take 2 tablets with water.

DIETARY_SUPPLEMENTPlacebo

Take 2 tablets (matching NP-2007) once a day with water.

Sponsors

Hanpoong Nature Pharm Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy females between 35 and 65 years of age 2. Subjects with dry skin (Skin capacitance ≤ 49 units measured by Corneometer® CM 825) 3. Subjects with eye wrinkles (grade 3 or higher based on visual assessment scale) 4. Subjects who voluntarily signed the informed consent form after receiving a full explanation of the study 5. Subjects who are available for follow-up visits at scheduled times throughout the study period

Exclusion criteria

* 1\) Subjects with skin diseases (atopic dermatitis, psoriasis, etc.) in the test area 2\) Subjects who have used skin-related medications (steroids, etc.) within 1 month 3\) Subjects with a history of hypersensitivity to the test ingredients or severe food allergies 4\) Pregnant or lactating women, or those planning to become pregnant 5\) Subjects who have participated in other clinical trials within the past 3 months 6\) Any other conditions that the investigator deems unsuitable for participation

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline in Skin Hydration at 12 weeksBaseline, 6 weeks, 12 weeksMeasured using Corneometer® CM 825. The unit of measure is arbitrary units (AU) ranging from 0 to 120. Higher scores indicate improved skin moisture.
Change from Baseline in Transepidermal Water Loss (TEWL) at 12 WeeksBaseline, 6 weeks, 12 weeksMeasured using Tewameter® TM 300. The unit of measure is g/m²/h. Lower values indicate improved skin barrier function.
Change from Baseline in Skin Scaling at 12 WeeksBaseline, 6 weeks, 12 weeksEvaluated using D-Squame® and image analysis. Higher values indicate more scaling (worse), lower values indicate improvement.
Change from Baseline in Skin Roughness at 12 WeeksBaseline, 6 weeks, 12 weeksMeasured using Visiometer® SV 700. Assesses the texture of the skin surface. Lower values indicate smoother skin.
Change from Baseline in Eye Wrinkles (Ra) at 12 WeeksBaseline, 6 weeks, 12 weeksQuantitative analysis of eye wrinkles (crow's feet) using Visiometer® SV 700. Ra represents the average roughness in millimeters (mm). Lower values indicate improved wrinkle depth.
Change from Baseline in Skin Elasticity (R2) at 12 WeeksBaseline, 6 weeks, 12 weeksMeasured using Cutometer® MPA 580. R2 represents gross elasticity (0 to 1 scale). Higher values indicate better skin elasticity.

Secondary

MeasureTime frameDescription
Investigator's Visual Assessment Grade for Eye WrinklesClinical grading of eye wrinkle severity by a dermatologist. The grade is based on a visual scale from 0 to 9 (0 = None, 9 = Very Severe). Lower grades indicate clinical improvement in wrinkle severity.Baseline, 6 weeks, 12 weeks Clinical grading of eye wrinkle severity by a dermatologist using a visual analog scale. The scale ranges from 0 to 9, where 0 indicates 'None' (no wrinkles) and 9 indicates 'Very Severe' wrinkles. A decrease in the score (lower values) represents a better outcome (improvement in wrinkles).
Participant Subjective Questionnaire Assessment for Skin ImprovementParticipants assess skin improvement and satisfaction through a self-report questionnaire using a 5-point Likert scale (1 = Very Dissatisfied, 5 = Very Satisfied). Higher scores indicate greater satisfaction with the product's efficacy.6 weeks, 12 weeks Participants' self-assessment of skin improvement using a 5-point Likert scale. The scale ranges from 1 to 5, where 1 indicates 'Very Dissatisfied' and 5 indicates 'Very Satisfied'. A higher score represents a better outcome (higher satisfaction and perceived efficacy).

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026